Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Seagen Inc.
Mirati Therapeutics Inc.
Taiho Oncology, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb
AstraZeneca
Revolution Medicines, Inc.
PrECOG, LLC.
Eli Lilly and Company
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Hoffmann-La Roche
Gilead Sciences
AstraZeneca
Revolution Medicines, Inc.
AstraZeneca
AbbVie
Pfizer
AbbVie
Allist Pharmaceuticals, Inc.
Fundación GECP
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
GlaxoSmithKline
University Medical Center Groningen
Genprex, Inc.
Shanghai Hengrui Pharmaceutical Co., Ltd.
University Health Network, Toronto
CSPC Megalith Biopharmaceutical Co.,Ltd.
Weill Medical College of Cornell University
Genelux Corporation
Eli Lilly and Company
Mirati Therapeutics Inc.
Hospital Sultanah Bahiyah
Iovance Biotherapeutics, Inc.
Peking University Cancer Hospital & Institute
Shanghai Junshi Bioscience Co., Ltd.
Shanghai Chest Hospital
Stanford University
Fundación GECP
Shanghai JMT-Bio Inc.
Goethe University